
Francesco Ernesto Pontieri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6555783/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Movement Disorders, 2009, 24, 1641-1649.	3.9	1,171
2	Cannabinoid and Heroin Activation of Mesolimbic Dopamine Transmission by a Common µ ₁ Opioid Receptor Mechanism. Science, 1997, 276, 2048-2050.	12.6	1,059
3	Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature, 1996, 382, 255-257.	27.8	1,015
4	Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 12304-12308.	7.1	783
5	Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain, 2010, 133, 3423-3433.	7.6	374
6	Drug Addiction as a Disorder of Associative Learning: Role of Nucleus Accumbens Shell/Extended Amygdala Dopamine. Annals of the New York Academy of Sciences, 1999, 877, 461-485.	3.8	204
7	The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. Journal of Neurology, 2012, 259, 2621-2631.	3.6	188
8	Contribution of Blockade of the Noradrenaline Carrier to the Increase of Extracellular Dopamine in the Rat Prefrontal Cortex by Amphetamine and Cocaine. European Journal of Neuroscience, 1997, 9, 2077-2085.	2.6	153
9	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. Journal of Neurology, 2010, 257, 5-14.	3.6	140
10	The recognition of facial emotion expressions in Parkinson's disease. European Neuropsychopharmacology, 2008, 18, 835-848.	0.7	97
11	Supine hypertension in Parkinson's disease and multiple system atrophy. Clinical Autonomic Research, 2016, 26, 97-105.	2.5	87
12	Neuropharmacology and behavior in planarians: Translations to mammals. Comparative Biochemistry and Pharmacology, 2008, 147, 399-408.	2.6	84
13	Prodromal non-motor symptoms of Parkinson's disease. Neuropsychiatric Disease and Treatment, 2007, 3, 145-151.	2.2	83
14	Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 76-82.	1.9	82
15	Behavioral sensitization to heroin by cannabinoid pretreatment in the rat. European Journal of Pharmacology, 2001, 421, R1-R3.	3.5	80
16	The Dopaminergic System in Peripheral Blood Lymphocytes: From Physiology to Pharmacology and Potential Applications to Neuropsychiatric Disorders. Current Neuropharmacology, 2011, 9, 278-288.	2.9	76
17	Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. Journal of Neural Transmission, 2001, 108, 803-807.	2.8	65
18	The potential prognostic role of cardiovascular autonomic failure in αâ€ s ynucleinopathies. European Journal of Neurology, 2013, 20, 231-235.	3.3	61

#	Article	IF	CITATIONS
19	Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease. NeuroReport, 1999, 10, 2907-2910.	1.2	58
20	Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study. Journal of Neurology, 2018, 265, 1124-1137.	3.6	52
21	Intensity-dependent facial emotion recognition and cognitive functions in Parkinson's disease. Journal of the International Neuropsychological Society, 2010, 16, 867-876.	1.8	49
22	Metabolic mapping of the effects of intravenous methamphetamine administration in freely moving rats. Psychopharmacology, 1990, 102, 175-182.	3.1	47
23	Amyotrophic lateral sclerosis and sports: a case–control study. European Journal of Neurology, 2005, 12, 223-225.	3.3	47
24	Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. Journal of Neurology, 2014, 261, 1291-1299.	3.6	47
25	Psychostimulant drugs increase glucose utilization in the shell of the rat nucleus accumbens. NeuroReport, 1994, 5, 2561-2564.	1.2	46
26	Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study. Journal of Neurology, 1996, 243, 422-425.	3.6	44
27	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	2.2	44
28	Acetylcholine/dopamine interaction in planaria. Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology, 2000, 125, 225-231.	0.5	40
29	Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurological Sciences, 2005, 26, 285-287.	1.9	39
30	An exploratory case-control study on spinal and bulbar forms of amyotrophic lateral sclerosis in the province of Rome. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 361-369.	2.1	39
31	Alexithymia Is a Non-Motor Symptom of Parkinson Disease. American Journal of Geriatric Psychiatry, 2012, 20, 133-141.	1.2	38
32	Blood Dendritic Cell Frequency Declines in Idiopathic Parkinson's Disease and Is Associated with Motor Symptom Severity. PLoS ONE, 2013, 8, e65352.	2.5	38
33	Foot Pressure Wearable Sensors for Freezing of Gait Detection in Parkinson's Disease. Sensors, 2021, 21, 128.	3.8	38
34	Neuropsychiatric and cognitive symptoms and body side of onset of parkinsonism in unmedicated Parkinson's disease patients. Parkinsonism and Related Disorders, 2015, 21, 1096-1100.	2.2	36
35	Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson× ³ s disease. European Neuropsychopharmacology, 2015, 25, 69-76.	0.7	35
36	Opioid–dopamine interaction in planaria: a behavioral study. Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology, 1999, 124, 51-55.	0.5	34

#	Article	IF	CITATIONS
37	Adrenal dysregulation in amyotrophic lateral sclerosis. Journal of Endocrinological Investigation, 2003, 26, RC23-RC25.	3.3	34
38	Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor. Journal of Neural Transmission, 2007, 114, 935-938.	2.8	34
39	Dopamine receptor mRNAs in the rat lymphocytes. Life Sciences, 1998, 62, 1919-1925.	4.3	33
40	Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. Parkinsonism and Related Disorders, 2015, 21, 1393-1397.	2.2	33
41	Application of the â€~5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. Neurodegenerative Disease Management, 2020, 10, 309-323.	2.2	33
42	Behavioral sensitization to WIN55212.2 in rats pretreated with heroin. Brain Research, 2001, 898, 178-180.	2.2	32
43	Anosognosia for cognitive and behavioral symptoms in Parkinson's disease with mild dementia and mild cognitive impairment: Frequency and neuropsychological/neuropsychiatric correlates. Parkinsonism and Related Disorders, 2018, 54, 62-67.	2.2	32
44	Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease. Parkinsonism and Related Disorders, 2017, 45, 50-56.	2.2	31
45	Drug Choices and Advancements for Managing Depression in Parkinson's Disease. Current Neuropharmacology, 2020, 18, 277-287.	2.9	31
46	Local cerebral glucose utilization after D1 receptor stimulation in 6-OHDA lesioned rats: Effect of sensitization (priming) with a dopaminergic agonist. Synapse, 1993, 13, 264-269.	1.2	30
47	Metabolic Mapping of the Effects of Win 55212–2 Intravenous Administration in the Rat. Neuropsychopharmacology, 1999, 21, 773-776.	5.4	29
48	Intravenous morphine increases glucose utilization in the shell of the rat nucleus accumbens. European Journal of Pharmacology, 1996, 302, 49-51.	3.5	26
49	Heroin sensitization as mapped by c-Fos immunoreactivity in the rat striatum. Brain Research, 2002, 933, 144-149.	2.2	26
50	Regional cortical thickness and cognitive functions in nonâ€demented Parkinson's disease patients: a pilot study. European Journal of Neurology, 2012, 19, 172-175.	3.3	26
51	Functional correlates of nicotine administration: similarity with drugs of abuse. Journal of Molecular Medicine, 1998, 76, 193-201.	3.9	25
52	Dopamine transporter immunoreactivity in peripheral blood mononuclear cells in amyotrophic lateral sclerosis. European Journal of Neurology, 2006, 13, 416-418.	3.3	25
53	Cannabinoid-induced stimulation of motor activity in planaria through an opioid receptor-mediated mechanism. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 65-68.	4.8	23
54	Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 871-875.	2.2	23

Francesco Ernesto Pontieri

#	Article	IF	CITATIONS
55	<scp>DUOGLOBE</scp> : Oneâ€Year Outcomes in a <scp>Realâ€World</scp> Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 1061-1074.	1.5	22
56	Early distinction of Parkinsonâ€variant multiple system atrophy from Parkinson's disease. Movement Disorders, 2019, 34, 440-441.	3.9	21
57	Functional correlates of heroin sensitization in the rat brain. European Journal of Pharmacology, 1997, 335, 133-137.	3.5	19
58	Central and peripheral dopamine transporter reduction in Parkinson's disease. Neurological Research, 2009, 31, 687-691.	1.3	19
59	Urinary retention discriminates multiple system atrophy from Parkinson's disease. Movement Disorders, 2019, 34, 1926-1928.	3.9	19
60	Alpha-synuclein in salivary gland as biomarker for Parkinson's disease. Reviews in the Neurosciences, 2019, 30, 455-462.	2.9	19
61	Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study. Journal of Neural Transmission, 2021, 128, 273-277.	2.8	19
62	Functional correlates of repeated administration of cocaine and apomorphine in the rat. European Journal of Pharmacology, 1995, 284, 205-209.	3.5	18
63	Differential effects of acute administration of clozapine or haloperidol on local cerebral glucose utilization in the rat1This study was partially supported by the Italian Health Department.1. Brain Research, 1997, 768, 273-278.	2.2	18
64	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. Neurological Sciences, 2012, 33, 585-593.	1.9	18
65	Changes in neuropeptide FF and NPY immunohistochemical patterns in rat brain under heroin treatment. Brain Research, 2006, 1083, 151-158.	2.2	17
66	Increased Lymphocyte Dopamine β-Hydroxylase Immunoreactivity in Alzheimer's Disease: Compensatory Response to Cholinergic Deficit?. Dementia and Geriatric Cognitive Disorders, 2004, 18, 338-341.	1.5	15
67	The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease. Journal of Neurology, 2014, 261, 1126-1132.	3.6	14
68	Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy. Journal of Neural Transmission, 2009, 116, 161-165.	2.8	13
69	Hemiparkinsonism due to frontal meningioma. Acta Neurologica Belgica, 2008, 108, 29-32.	1.1	13
70	The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study. European Journal of Medical Research, 2013, 18, 60.	2.2	12
71	HEDONIC TONE AND ITS MOOD AND COGNITIVE CORRELATES IN PARKINSON'S DISEASE. Depression and Anxiety, 2013, 30, 85-91.	4.1	11
72	Phosphorylated α-synuclein immunoreactivity in nerve fibers from minor salivary glands in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 38, 99-101.	2.2	11

#	Article	IF	CITATIONS
73	Action Observation With Dual Task for Improving Cognitive Abilities in Parkinson's Disease: A Pilot Study. Frontiers in Systems Neuroscience, 2019, 13, 7.	2.5	11
74	Metabolic mapping of the synergism between MK-801 and SKF 38393 in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. Synapse, 1992, 12, 255-260.	1.2	10
75	Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson's disease. Movement Disorders, 2011, 26, 355-357.	3.9	10
76	Botulinum toxin type A for Holmes tremor secondary to thalamic hemorrhage. Neurological Sciences, 2015, 36, 1935-1936.	1.9	10
77	Orthostatic hypotension acutely impairs executive functions in Parkinson's disease. Neurological Sciences, 2018, 39, 1459-1462.	1.9	10
78	Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study. Neurological Sciences, 2018, 39, 141-143.	1.9	10
79	Treatment with 6-hydroxydopamine in planaria (Dugesia gonocephala s.l.): morphological and behavioral study. Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology, 1999, 123, 201-207.	0.5	9
80	Rotigotine for anxiety during wearing-off in Parkinson's disease with dementia. Aging Clinical and Experimental Research, 2013, 25, 601-603.	2.9	9
81	Gender specific decrease of a set of circulating N-acylphosphatidyl ethanolamines (NAPEs) in the plasma of Parkinson's disease patients. Metabolomics, 2019, 15, 74.	3.0	9
82	Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism. Brain and Behavior, 2019, 9, e01448.	2.2	9
83	<p>Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2899-2912.	2.2	9
84	Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease. Journal of Personalized Medicine, 2021, 11, 51.	2.5	9
85	Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study. Neurological Research, 2021, 43, 950-954.	1.3	9
86	Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel. Journal of Parkinson's Disease, 2022, 12, 917-926.	2.8	9
87	Alterations in opiate receptor binding in MPTP-induced hemiparkinsonian monkeys. Neuroscience Letters, 1991, 127, 155-159.	2.1	8
88	Depressive symptoms in Parkinson's disease and in non-neurological medical illnesses. Neuropsychiatric Disease and Treatment, 2013, 9, 389.	2.2	8
89	Treatment with botulinum toxin for anti-MAG neuropathy-related arm tremor. Neurological Sciences, 2015, 36, 333-334.	1.9	8
90	The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. Journal of Neural Transmission, 2020, 127, 881-891.	2.8	8

#	Article	IF	CITATIONS
91	Immune System and Neuroinflammation in Idiopathic Parkinson's Disease: Association Analysis of Genetic Variants and miRNAs Interactions. Frontiers in Genetics, 2021, 12, 651971.	2.3	8
92	The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study. Aging Clinical and Experimental Research, 2021, 33, 1689-1692.	2.9	7
93	Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study. Neurological Research, 2009, 31, 74-76.	1.3	6
94	Dopaminergic system in peripheral blood mononuclear cells in Parkinson's disease. Movement Disorders, 2010, 25, 125-126.	3.9	6
95	Neuropharmacology of Cannabinoid System: From Basic Science to Clinical Applications. Current Neuropharmacology, 2004, 2, 1-7.	2.9	6
96	Cerebellar GABA Levels and Cognitive Interference in Parkinson's disease and Healthy Comparators. Journal of Personalized Medicine, 2021, 11, 16.	2.5	6
97	Increased motor response to cocaine administration following recovery from chronic corticosterone treatment in the rat. European Neuropsychopharmacology, 1998, 8, 43-46.	0.7	5
98	Effects of intra-VTA injection of neurotensin on local cerebral glucose utilization in freely moving ratsâ~†,â~†â~†. Peptides, 2000, 21, 1751-1753.	2.4	5
99	Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease. Pharmacological Reports, 2011, 63, 1056-1060.	3.3	4
100	Psychiatric profile of motor subtypes of de novo drugâ€naÃ⁻ve Parkinson's disease patients. Brain and Behavior, 2018, 8, e01094.	2.2	4
101	Percutaneous endoscopic gastrojejunostomy in pediatric intestinal pseudo-obstruction. Nutrition, 2021, 86, 111174.	2.4	4
102	Selective metabolic activation by apomorphine in striosomes of denervated striatum in MPTP-induced hemiparkinsonian monkeys. NeuroReport, 1995, 6, 1330-1332.	1.2	3
103	Effects of haloperidol on the expression of lymphocyte dopamine receptor mRNAS in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1999, 23, 851-859.	4.8	3
104	Choline acetyltransferase of the common type immunoreactivity in the rat brain following different heroin treatments: A pilot study. Journal of Chemical Neuroanatomy, 2011, 41, 111-121.	2.1	3
105	Dopamine release in striatal slices of rats previously submitted to electroconvulsive shock. Brain Research, 1997, 774, 239-241.	2.2	2
106	Electroconvulsive shock blocks the opioid-mediated inhibition of dopamine release in rat striatal slices. Journal of Neural Transmission, 1997, 104, 805-810.	2.8	2
107	Unraveling predictors affecting compliance to MRI inÂParkinson'sÂdisease. Parkinsonism and Related Disorders, 2015, 21, 964-967.	2.2	2
108	Validation of the Canadian Occupational Performance Measure in Italian Parkinson's Disease Clients. Physical and Occupational Therapy in Geriatrics, 2022, 40, 26-37.	0.4	2

#	Article	IF	CITATIONS
109	Increased functional response to cocaine challenge following recovery from chronic corticosterone in the rat. European Journal of Pharmacology, 1997, 336, 159-162.	3.5	1
110	Effects of the intravenous administration of [Lys7]dermorphin on local cerebral glucose utilization in the rat. European Journal of Pharmacology, 2006, 544, 17-20.	3.5	1
111	On the relationship between side of onset and cognition in Parkinson disease: Response from the authors. Parkinsonism and Related Disorders, 2015, 21, 1481-1482.	2.2	1
112	Levodopa/carbidopa intestinal gel for pain related to levodopa-induced motor complications in Parkinson's disease. Neurological Sciences, 2022, , 1.	1.9	1
113	Plasma Exchangeâ€responsive Tardive Delayed Pseudochoreoathetosis in a Patient with Antiâ€Hu Neuronopathy. Movement Disorders Clinical Practice, 2017, 4, 887-888.	1.5	0